ECSP109965A - Imidazoles fusionados para el tratamiento del cancer - Google Patents
Imidazoles fusionados para el tratamiento del cancerInfo
- Publication number
- ECSP109965A ECSP109965A EC2010009965A ECSP109965A ECSP109965A EC SP109965 A ECSP109965 A EC SP109965A EC 2010009965 A EC2010009965 A EC 2010009965A EC SP109965 A ECSP109965 A EC SP109965A EC SP109965 A ECSP109965 A EC SP109965A
- Authority
- EC
- Ecuador
- Prior art keywords
- fusionated
- imidazoles
- cancer
- treatment
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Compuestos de fórmula (I); tautómeros o estereoisómeros de éstos, o sus sales, donde el anillo B y el imidazol al que está fusionado, R4, R6, y R7 tienen los significados indicados en la descripción y las reivindicaciones, que son inhibidores eficaces de la vía Pi3K/Akt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1573MU2007 | 2007-08-14 | ||
EP07118733A EP2062893A1 (en) | 2007-10-18 | 2007-10-18 | Fused imidazoles for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP109965A true ECSP109965A (es) | 2010-03-31 |
Family
ID=39876840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010009965A ECSP109965A (es) | 2007-08-14 | 2010-02-12 | Imidazoles fusionados para el tratamiento del cancer |
Country Status (24)
Country | Link |
---|---|
US (2) | US8592591B2 (es) |
EP (1) | EP2176259B1 (es) |
JP (1) | JP5327652B2 (es) |
KR (1) | KR20100049589A (es) |
CN (1) | CN101835776A (es) |
AR (1) | AR067946A1 (es) |
AT (1) | ATE503757T1 (es) |
AU (1) | AU2008288390A1 (es) |
CA (1) | CA2695251C (es) |
CL (1) | CL2008002397A1 (es) |
CR (1) | CR11271A (es) |
DE (1) | DE602008005894D1 (es) |
DO (1) | DOP2010000057A (es) |
EA (1) | EA201000297A1 (es) |
EC (1) | ECSP109965A (es) |
MA (1) | MA31609B1 (es) |
MX (1) | MX2010001745A (es) |
PA (1) | PA8793301A1 (es) |
PE (1) | PE20090596A1 (es) |
SV (1) | SV2010003482A (es) |
TN (1) | TN2010000071A1 (es) |
TW (1) | TW200924761A (es) |
UY (1) | UY31292A1 (es) |
WO (1) | WO2009021990A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410087B2 (en) * | 2006-10-19 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Indole compound |
CN101835776A (zh) * | 2007-08-14 | 2010-09-15 | 拜耳先灵医药股份有限公司 | 用于癌症治疗的稠合的咪唑 |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2010006086A2 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
CN102361872B (zh) * | 2009-02-13 | 2014-12-03 | 拜耳知识产权有限责任公司 | 作为akt抑制剂的稠合嘧啶 |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
US20120071475A1 (en) | 2009-04-27 | 2012-03-22 | Shionogi & Co., Ltd. | Urea derivatives having pi3k-inhibiting activity |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
CN102596961B (zh) | 2009-10-30 | 2015-12-02 | 詹森药业有限公司 | 咪唑并[1,2-b]哒嗪衍生物及其作为PDE10抑制剂的用途 |
WO2011053476A1 (en) * | 2009-11-02 | 2011-05-05 | Abbott Laboratories | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
WO2011089400A1 (en) * | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
ES2552841T3 (es) * | 2010-07-12 | 2015-12-02 | Bayer Intellectual Property Gmbh | Imidazo[1,2-a]pirimidinas y -piridinas sustituidas |
CA2806655A1 (en) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
EP2698372B1 (en) * | 2011-04-06 | 2016-02-03 | Taiho Pharmaceutical Co., Ltd. | Novel imidazo-oxazine compound or salt thereof |
EA024890B1 (ru) * | 2011-04-07 | 2016-10-31 | Байер Интеллектчуал Проперти Гмбх | Имидазопиридазины в качестве ингибиторов akt киназы |
BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
CN104066735B (zh) * | 2012-01-10 | 2016-08-31 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的咪唑并吡嗪 |
JP6106694B2 (ja) | 2012-01-10 | 2017-04-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Aktキナーゼ阻害剤としての置換ピラゾロピリミジン類 |
AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
NO2868660T3 (es) * | 2012-07-02 | 2018-05-26 | ||
ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
GB201321732D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
ES2772682T3 (es) | 2015-02-27 | 2020-07-08 | Taiho Pharmaceutical Co Ltd | Cristal de imidazooxazina, composición farmacéutica que contiene dicho cristal, y método de producción de dicho cristal |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
WO2018081167A1 (en) * | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Compounds and uses thereof |
EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE361297T1 (de) | 2000-03-31 | 2007-05-15 | Ortho Mcneil Pharm Inc | Phenyl-substituierte imidazopyridine |
CN1173975C (zh) * | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
EP1622616B1 (en) * | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
BRPI0412636A (pt) * | 2003-07-30 | 2006-09-26 | S A L V A T Lab Sa | imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer |
ATE499364T1 (de) | 2004-04-09 | 2011-03-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
US7544677B2 (en) * | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
EP1827436A4 (en) * | 2004-12-15 | 2011-08-10 | Merck Sharp & Dohme | ACTIVITY INHIBITORS AKT |
JP2008540674A (ja) * | 2005-05-20 | 2008-11-20 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1928237A4 (en) * | 2005-09-02 | 2011-03-09 | Abbott Lab | NEW HETEROCYCLES BASED ON IMIDAZO |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
US7530313B2 (en) | 2006-05-12 | 2009-05-12 | Day & Zimmerman, Inc. | Self-destruct fuze delay mechanism |
CN101835776A (zh) * | 2007-08-14 | 2010-09-15 | 拜耳先灵医药股份有限公司 | 用于癌症治疗的稠合的咪唑 |
-
2008
- 2008-08-14 CN CN200880103578A patent/CN101835776A/zh active Pending
- 2008-08-14 TW TW097131067A patent/TW200924761A/zh unknown
- 2008-08-14 AT AT08787222T patent/ATE503757T1/de not_active IP Right Cessation
- 2008-08-14 WO PCT/EP2008/060686 patent/WO2009021990A1/en active Application Filing
- 2008-08-14 JP JP2010520584A patent/JP5327652B2/ja not_active Expired - Fee Related
- 2008-08-14 US US12/191,706 patent/US8592591B2/en not_active Expired - Fee Related
- 2008-08-14 PA PA20088793301A patent/PA8793301A1/es unknown
- 2008-08-14 DE DE602008005894T patent/DE602008005894D1/de active Active
- 2008-08-14 CA CA2695251A patent/CA2695251C/en not_active Expired - Fee Related
- 2008-08-14 CL CL2008002397A patent/CL2008002397A1/es unknown
- 2008-08-14 EP EP08787222A patent/EP2176259B1/en active Active
- 2008-08-14 AU AU2008288390A patent/AU2008288390A1/en not_active Abandoned
- 2008-08-14 KR KR1020107003250A patent/KR20100049589A/ko not_active Application Discontinuation
- 2008-08-14 UY UY31292A patent/UY31292A1/es not_active Application Discontinuation
- 2008-08-14 PE PE2008001379A patent/PE20090596A1/es not_active Application Discontinuation
- 2008-08-14 MX MX2010001745A patent/MX2010001745A/es not_active Application Discontinuation
- 2008-08-14 EA EA201000297A patent/EA201000297A1/ru unknown
- 2008-08-15 AR ARP080103563A patent/AR067946A1/es unknown
-
2010
- 2010-02-12 DO DO2010000057A patent/DOP2010000057A/es unknown
- 2010-02-12 EC EC2010009965A patent/ECSP109965A/es unknown
- 2010-02-12 MA MA32618A patent/MA31609B1/fr unknown
- 2010-02-12 CR CR11271A patent/CR11271A/es not_active Application Discontinuation
- 2010-02-12 TN TNP2010000071A patent/TN2010000071A1/fr unknown
- 2010-02-12 SV SV2010003482A patent/SV2010003482A/es not_active Application Discontinuation
-
2013
- 2013-11-26 US US14/090,367 patent/US9387204B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW200924761A (en) | 2009-06-16 |
EP2176259A1 (en) | 2010-04-21 |
PA8793301A1 (es) | 2009-04-23 |
CN101835776A (zh) | 2010-09-15 |
DOP2010000057A (es) | 2010-04-15 |
CL2008002397A1 (es) | 2009-09-25 |
AR067946A1 (es) | 2009-10-28 |
UY31292A1 (es) | 2009-03-31 |
JP5327652B2 (ja) | 2013-10-30 |
CA2695251C (en) | 2016-06-21 |
SV2010003482A (es) | 2010-07-06 |
TN2010000071A1 (en) | 2011-09-26 |
US8592591B2 (en) | 2013-11-26 |
US9387204B2 (en) | 2016-07-12 |
CA2695251A1 (en) | 2009-02-19 |
MA31609B1 (fr) | 2010-08-02 |
JP2010535847A (ja) | 2010-11-25 |
KR20100049589A (ko) | 2010-05-12 |
US20090156604A1 (en) | 2009-06-18 |
AU2008288390A1 (en) | 2009-02-19 |
EP2176259B1 (en) | 2011-03-30 |
ATE503757T1 (de) | 2011-04-15 |
EA201000297A1 (ru) | 2010-08-30 |
DE602008005894D1 (de) | 2011-05-12 |
PE20090596A1 (es) | 2009-06-07 |
CR11271A (es) | 2010-05-19 |
US20140088110A1 (en) | 2014-03-27 |
WO2009021990A1 (en) | 2009-02-19 |
MX2010001745A (es) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP109965A (es) | Imidazoles fusionados para el tratamiento del cancer | |
UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
CR11803A (es) | Pirrolopiridinas como inhibidores de cinasa | |
GT200600394A (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis. | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
CL2008002398A1 (es) | Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer. | |
CO6170360A2 (es) | Derivados de pirimidinil - piridazinona | |
ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
CL2014000887A1 (es) | Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer. | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
ECSP088984A (es) | Derivados de triazol ii | |
UY32432A (es) | Compuestos de pirimidina fusionada como inhibidores de akt | |
ECSP066882A (es) | Compuestos de imidazol | |
ECSP10010510A (es) | Compuestos del inhibidor de raf y métodos de uso de los mismos | |
CR11412A (es) | Inhibidores de cinesina como productos terapeuticos para el cancer | |
AR059294A1 (es) | Derivados de indazol-heteroarilo | |
ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
EA201200087A1 (ru) | 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k | |
EA201070599A1 (ru) | Ингибиторы равновесного переносчика нуклеозидов ent1 | |
CL2023002486A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
EA201590656A1 (ru) | Азаиндолины | |
AR059617A1 (es) | Derivados de aminopirimidina, medicamentos que los contienen, y usos para el tratamiento de enfermedades en las que la regulacion, inhibicion y/o la modulacion de la hsp90 desempena un papel importante. | |
CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
UA117809C2 (uk) | Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку |